iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Zydus Lifesciences Ltd News Today

981.8
(-0.02%)
Jun 27, 2025|12:00:00 AM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Company

Sectoral

Zydus Lifesciences’ oncology unit gets 2 USFDA observations

In its filing with the bourses, Zydus informed that these observations received were minor, and not related to data integrity.

19 Jun 2025|12:36 PM
Top Stocks for Today - 19th June 2025

Here are some of the stocks that may see significant price movement today: Jio Financial Service, Hero MotoCorp, Abbott India, etc.

19 Jun 2025|06:28 AM
Top Stocks for Today - 12th June 2025

Here are some of the stocks that may see significant price movement today: Hindustan Copper, Maruti Suzuki, Zydus Lifesciences, etc.

12 Jun 2025|06:12 AM
Zydus Lifesciences Gets Clean USFDA Nod for Ankleshwar API Facility

For Zydus, this clean report adds a layer of credibility to its US compliance track record especially since the Ankleshwar facility is a key site for its API exports.

11 Jun 2025|08:40 PM
Zydus Lifesciences Subsidiary Zynext to Acquire 5.9% Stake in Agenus for $16 Million

The acquisition is priced at $7.50 per share and will be completed in cash within 60 days, subject to regulatory approvals

3 Jun 2025|11:05 PM
Zydus Gets USFDA Fast Track Nod for ALS Drug Usnoflast

It provides benefits such as faster approval, priority review and a more open line of communication with the F.D.A.

29 May 2025|10:53 AM
Zydus Lifesciences Gets USFDA Nod for Generic Absorica to Treat Severe Acne

They are the generic form of Absorica, a well-known prescription treatment for severe and hard to treat forms of nodular acne that the patient has not responded well to other treatments with.

24 May 2025|08:15 PM
Zydus Lifesciences Q4 Revenue Rises 18% YoY to ₹6,528 Crore

Consolidated revenue for the March quarter rose 18% YoY to ₹6,528 crore.

22 May 2025|12:16 PM
Zydus Wins USFDA Approval for Cholesterol Drug

The medication is also prescribed to lower the risk of another heart attack in individuals with a past history of myocardial infarction and hyperlipidaemia

30 Apr 2025|11:25 PM
Zydus Lifesciences Gets USFDA Nod for Niacin ER Tablets in Multiple Strengths

USFDA's final approval is available for Zydus Lifesciences and group companies, and this will allow the group to sell the product in the highly regulated US market.

30 Apr 2025|03:28 PM
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.